Novocure Company Insiders

NVCR Stock  USD 19.59  0.10  0.51%   
Novocure's insiders are aggressively selling. The analysis of insiders' sentiment of trading Novocure stock suggests that virtually all insiders are panicking at this time. Novocure employs about 1.5 K people. The company is managed by 18 executives with a total tenure of roughly 42 years, averaging almost 2.0 years of service per executive, having 82.67 employees per reported executive.
Asaf Danziger  CEO
CEO and Director
William Doyle  Chairman
Executive Chairman

Insider Sentiment 0

 Mostly Selling

 
Selling
 
Buying

Latest Trades

2024-11-01Mukund ParavasthuDisposed 160 @ 15.88View
2024-10-31Michal Nath PuriDisposed 810 @ 15.79View
2024-08-02Ashley CordovaDisposed 688 @ 20.14View
2024-06-04W Anthony VernonDisposed 964 @ 23.89View
Monitoring Novocure's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novocure. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
To learn how to invest in Novocure Stock, please use our How to Invest in Novocure guide.

Novocure's Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Novocure's future performance. Based on our forecasts, it is anticipated that Novocure will maintain a workforce of slightly above 1490 employees by April 2025.
 
Yuan Drop
 
Covid

Novocure Management Team Effectiveness

The company has return on total asset (ROA) of (0.0877) % which means that it has lost $0.0877 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4667) %, meaning that it created substantial loss on money invested by shareholders. Novocure's management efficiency ratios could be used to measure how well Novocure manages its routine affairs as well as how well it operates its assets and liabilities. As of 03/18/2025, Return On Tangible Assets is likely to drop to -0.14. In addition to that, Return On Capital Employed is likely to drop to -0.37. At this time, Novocure's Non Current Assets Total are relatively stable compared to the past year. As of 03/18/2025, Non Currrent Assets Other is likely to grow to about 15.3 M, while Net Tangible Assets are likely to drop slightly above 267.8 M.
As of 03/18/2025, Common Stock Shares Outstanding is likely to drop to about 98 M. In addition to that, Net Loss is likely to drop to about (111.7 M)

Novocure Workforce Comparison

Novocure is rated below average in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 44,737. Novocure holds roughly 1,488 in number of employees claiming about 3% of equities under Health Care industry.

Novocure Profit Margins

The company has Profit Margin (PM) of (0.28) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.39) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.39.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.50.7733
Way Down
Slightly volatile

Novocure Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Novocure insiders, such as employees or executives, is commonly permitted as long as it does not rely on Novocure's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Novocure insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Yuan Drop
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2025-03-01
0.85
17
20
 1,730,622 
 44,817 
2024-12-01
0.8333
5
6
 77,212 
 14,052 
2024-06-01
4.6
23
5
 214,611 
 134,958 
2024-03-01
0.6667
16
24
 1,489,515 
 179,501 
2023-12-01
1.6
8
5
 113,296 
 18,350 
2023-03-01
0.7292
35
48
 734,199 
 523,934 
2022-12-01
1.0
3
3
 20,439 
 15,508 
2022-09-01
0.6111
11
18
 14,868 
 52,862 
2022-06-01
0.6
12
20
 75,778 
 41,208 
2022-03-01
1.0417
25
24
 325,126 
 64,060 
2021-12-01
3.0
3
1
 4,974 
 209.00 
2021-09-01
0.3878
19
49
 44,261 
 189,462 
2021-06-01
0.449
22
49
 37,681 
 276,842 
2021-03-01
0.4839
30
62
 311,025 
 225,346 
2020-12-01
0.1818
6
33
 136,907 
 452,153 
2020-09-01
0.3094
43
139
 353,770 
 952,382 
2020-06-01
0.6875
22
32
 406,132 
 644,730 
2020-03-01
0.9444
34
36
 1,158,839 
 994,692 
2019-12-01
0.3425
25
73
 380,407 
 1,962,118 
2019-09-01
0.3176
27
85
 346,771 
 953,298 
2019-06-01
0.76
57
75
 1,767,677 
 2,181,883 
2019-03-01
0.6032
76
126
 2,143,248 
 3,266,745 
2018-12-01
0.6667
4
6
 48,781 
 81,412 
2018-09-01
0.2241
13
58
 191,500 
 1,305,170 
2018-06-01
0.5068
37
73
 1,999,659 
 2,047,679 
2018-03-01
1.3182
29
22
 1,622,166 
 642,328 
2017-09-01
0.3333
6
18
 367,195 
 1,081,938 
2017-06-01
0.1429
8
56
 1,887,536 
 1,803,696 
2017-03-01
1.2667
19
15
 9,650,031 
 23,718,725 
2016-12-01
0.0667
1
15
 156,073 
 338,573 
2016-09-01
0.1111
1
9
 676,576 
 1,353,152 
2016-06-01
1.2727
14
11
 1,678,771 
 1,804,779 
2016-03-01
8.0
8
1
 1,137,984 
 332,984 
2015-12-01
0.1867
14
75
 37,400,959 
 46,737,117 

Novocure Notable Stakeholders

A Novocure stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Novocure often face trade-offs trying to please all of them. Novocure's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Novocure's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Asaf DanzigerCEO and DirectorProfile
William DoyleExecutive ChairmanProfile
Piet MDHead VPProfile
Barak BenAryeGeneral CounselProfile
William BurkeChief OfficerProfile
Frank LeonardExecutive OncologyProfile
Christoph BrackmannChief OfficerProfile
Uri MDChief OfficerProfile
Pritesh ShahChief Commercial OfficerProfile
Ashley CordovaChief OfficerProfile
Moshe GiladiChief OfficerProfile
Wilhelmus GroenhuysenChief OfficerProfile
Pr MDFounder CTOProfile
MBA MDChief OfficerProfile
Ingrid GoldbergVP RelationsProfile
Barak AryeGeneral CounselProfile
Mukund ParavasthuChief OfficerProfile
Michael PuriChief OfficerProfile

About Novocure Management Performance

The success or failure of an entity such as Novocure often depends on how effective the management is. Novocure management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Novocure management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Novocure management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.14)(0.14)
Return On Capital Employed(0.35)(0.37)
Return On Assets(0.14)(0.14)
Return On Equity(0.47)(0.49)

Novocure Workforce Analysis

Traditionally, organizations such as Novocure use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Novocure within its industry.

Novocure Manpower Efficiency

Return on Novocure Manpower

Revenue Per Employee406.7K
Revenue Per Executive33.6M
Net Loss Per Employee113.3K
Net Loss Per Executive9.4M
Working Capital Per Employee235.3K
Working Capital Per Executive19.5M

Additional Tools for Novocure Stock Analysis

When running Novocure's price analysis, check to measure Novocure's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novocure is operating at the current time. Most of Novocure's value examination focuses on studying past and present price action to predict the probability of Novocure's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novocure's price. Additionally, you may evaluate how the addition of Novocure to your portfolios can decrease your overall portfolio volatility.